DCM Shriram’s record is clean on its face: a stable promoter holding with zero pledge, and an orderly auditor transition from PwC to Deloitte. Three things deserve attention: net debt has climbed to ₹1,767 crore while the company repeatedly failed to meet SEBI’s mandatory requirement for large corporates to raise 25% of incremental borrowings via debt securities; the Bioseed group was substantially written down, yet two FY26 acquisitions have added ₹57.69 crore of goodwill and a pending purchase-price allocation for a loss-making target; and government subsidy accruals remain a persistent auditor focus, with pending claims swinging sharply and receivables rising again.
Key findings
- Net debt rose 27% while the company repeatedly failed to meet SEBI’s mandatory borrowing requirement
Major- Consolidated net debt increased from ₹1,395 crore to ₹1,767 crore during FY26, a rise of ₹372 crore. The company was identified as a Large Corporate required to raise 25% of incremental borrowings via debt securities for both FY2023-24 and FY2024-25 but did not raise the required amount in either year, citing “most optimal cost of funds”. The Board Finance Committee approved NCDs up to ₹440 crore on 11 March 2026, but the deed of hypothecation was yet to be executed as of the Secretarial Audit Report date. - Subsidiary investments in the Bioseed group were substantially written down, while two FY26 acquisitions added goodwill and a pending purchase-price allocation
Major- As at 31 March 2022, cumulative impairment on subsidiary investments and loans stood at ₹108.73 crore, with the net worth of most subsidiaries substantially eroded and three Bioseed entities fully impaired to nil. The FY26 acquisition of 53% of DNV Global for ₹45.15 crore resulted in goodwill of ₹24.52 crore. The FY26 acquisition of Hindusthan Speciality Chemicals for ₹65.45 crore has its purchase-price allocation in progress, with a provisional goodwill of ₹33.17 crore already recognised, while the entity reported a post-acquisition loss of ₹14.86 crore and a pro-forma full-year loss of ₹48.03 crore. - Government subsidy accruals are a persistent auditor Key Audit Matter, with pending claims swinging sharply and receivables rising again
Minor- The auditor flagged subsidy accruals as a Key Audit Matter in each of FY21 through FY24, citing net accruals ranging from ₹683.98 crore to ₹1,775.88 crore. Urea subsidy claims pending government acceptance swung from ₹126.11 crore (March 2020) to ₹8.15 crore (March 2021) to ₹312.86 crore (March 2022) to ₹157.62 crore (March 2023). Fertilizer subsidy outstanding receivable rose 17% to ₹189 crore as of March 2026. - A one-time deferred-tax credit of ₹239 crore and an exceptional labour-code provision shape FY26 earnings, while prior years show recurring reliance on provision reversals
Minor- The company elected the lower tax regime under Section 115BAA, triggering a one-time deferred-tax credit of ₹239.48 crore in the standalone profit and loss statement. An additional provision of ₹23.38 crore for the new Labour Codes was presented as an exceptional item. Prior years show a pattern: FY24 included ₹4.53 crore of prior-period urea subsidy, FY20 included a ₹22.25 crore coal-provision reversal, and FY19 included a ₹38 crore reversal of provision for doubtful claims. - Contingent liabilities span a decade-old Supreme Court SLP, a ₹188-crore transfer-pricing dispute, and a ₹57-crore seed-compensation writ
Minor- The Group has not accrued benefits under the Sugar Industrial Promotion Policy 2004 because the State Government filed an SLP with the Supreme Court after the Allahabad High Court set aside its withdrawal on 12 February 2019. Income-tax litigation for AYs 2015-16 to 2018-19 carries a cumulative tax effect of ₹188.49 crore involving transfer-pricing adjustments, though the same issue was decided in the company’s favour for AY 2014-15 by ITAT. A writ petition challenges a direction to pay compensation of \~₹56.86 crore for Pink Boll Worm infestation, with show-cause notices served in 2018. - A family-controlled board with three brothers and a son in executive roles has secured multi-year reappointments and rising pay
Minor- The Board includes four Managing Directors and one Whole-time Director, with brothers Ajay S., Vikram S., and Ajit S. Shriram and Ajay’s son Aditya A. Shriram holding executive roles. Total remuneration for the three brothers in FY26 was Rs. 1,779.64 lakhs, Rs. 1,775.90 lakhs, and Rs. 1,621.38 lakhs respectively, with commission forming roughly half of each total. At the 25 July 2023 AGM, the resolution to appoint Aditya A. Shriram as Deputy Managing Director drew 78.49% votes against from public institutions, the highest dissent in the dossier. - The group actively reshapes its perimeter through acquisitions, divestments, and entity liquidations, while two subsidiaries remain on a liquidation basis
Minor- Two subsidiaries prepared financial statements on a liquidation basis as of 31 March 2026: DCM Shriram Infrastructure (assets ₹10.34 crore, liabilities ₹10.01 crore) and Bioseed India (assets and liabilities ₹0.01 crore each). During FY26, the company acquired stakes in DNV Global and Hindusthan Speciality Chemicals, incorporated Shriram Farm Solutions, and post-year-end sold a 50% stake in Shriram Polytech to Teknor Apex for USD 5.6 million. Two Section 8 foundations were not consolidated in FY21 because “the objective of control is not to obtain economic benefits” and were consolidated from 1 April 2024. - Deloitte replaced PwC as statutory auditor in FY23 after PwC completed its five-year term; Deloitte has since been re-confirmed through FY27 with no resignations
Clean- PwC served from the 28th AGM for five years until the 33rd AGM, when Deloitte was appointed for a five-year term ending at the 38th AGM in 2027 with 99.64% votes in favour. No statutory auditor resigned during any disclosed year. Total audit-network fees rose from ₹1.05 crore in FY21 to ₹3.09 crore in FY26.
What to watch
- Supreme Court SLP on sugar policy. The State Government’s SLP against the 12 February 2019 Allahabad High Court order remains pending.
- Transfer-pricing litigation. Resolution of the ₹188.49 crore cumulative tax effect for AYs 2015-16 to 2018-19, pending at CIT(A) and ITAT as of 14 March 2024.
- Urea subsidy finalisation. Claims of ₹189.46 crore pending notification or acceptance by FICC as of 31 March 2026.
- Hindusthan Speciality Chemicals purchase-price allocation. Completion of the allocation and determination of final goodwill or capital reserve, in progress as of the FY26 Annual Report.
- SEBI Large Corporate borrowing compliance. Whether the company meets the 25% requirement for FY2025-26, given non-compliance in the two preceding years and that the deed of hypothecation for the ₹440 crore NCDs approved on 11 March 2026 was yet to be executed as of the Secretarial Audit Report date.
Bottom line: This is a disclosed and audited record. The risk sits in three places: the combination of rising net debt and repeated SEBI non-compliance, the goodwill and pending purchase-price allocation on two acquisitions against a backdrop of prior subsidiary impairment, and the persistent reliance on government subsidy accruals that swing sharply with administrative acceptance. Watch the subsidy receivables line, the purchase-price allocation for Hindusthan Speciality Chemicals, and whether the company finally meets the SEBI borrowing requirement.